期刊名称 | Molecular Medicine MOL MED |
---|---|
期刊ISSN | 1076-1551 |
期刊官方网站 | https://molmed.biomedcentral.com |
是否OA | Yes |
出版商 | BioMed Central Ltd |
出版周期 | Bimonthly |
文章处理费 | 登录后查看 |
始发年份 | 1994 |
年文章数 | 164 |
影响因子 | 6.0(2023) scijournal影响因子 greensci影响因子 |
大类学科 | 小类学科 | Top | 综述 |
---|---|---|---|
医学3区 | BIOCHEMISTRY & MOLECULAR BIOLOGY 生化与分子生物学3区 | 否 | 否 |
CELL BIOLOGY 细胞生物学4区 | |||
MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验3区 |
CiteScore排名 | CiteScore | SJR | SNIP | ||
---|---|---|---|---|---|
学科 | 排名 | 百分位 | 8.6 | 1.446 | 0.907 |
Medicine Genetics (clinical) |
15/99 | 85% |
|||
Biochemistry, Genetics and Molecular Biology Genetics |
63/347 | 81% |
|||
Biochemistry, Genetics and Molecular Biology Molecular Biology |
103/410 | 75% |
|||
Biochemistry, Genetics and Molecular Biology Molecular Medicine |
47/178 | 73% |
自引率 | 1.7% |
---|---|
H-index | 110 |
SCI收录状况 |
Science Citation Index Expanded |
官方审稿时间 | 登录后查看 |
网友分享审稿时间 | 数据统计中,敬请期待。 |
接受率 | 登录后查看 |
PubMed Central (PMC) | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1076-1551%5BISSN%5D |
期刊投稿网址 | https://www.editorialmanager.com/mome |
---|---|
收稿范围 | Molecular Medicine is an open access journal publishing recent findings that elucidate disease pathogenesis at the molecular or physiological level, which may lead to the design of specific tools for disease diagnosis, treatment, or prevention. Manuscripts containing material relevant to the genetic, molecular, or cellular basis of key physiologic or disease processes are considered for publication. Manuscripts submitted to Molecular Medicine should describe the implications of the results for human disease and medicine, at a level approachable by our broad audience. Criteria to consider for studies involving lnc-RNAs or micro-RNAs: · As lncRNAs and miRNAs have multiple targets, claims of their function mediated by a single target or pathway will not be accepted, unless multiple additional targets are investigated to support functional specificity. · The rationale to investigate a specific lncRNA or miRNA needs to be specified upfront in the introduction and justified in the context of other miRNAs known to be functional in that specific field. · The proposed function of the lnc-RNA or miRNA should be validated by gain and loss of function studies. · Primary cells should be used whenever possible to confirm findings in cell lines. · In depth investigation in the signaling pathway(s) regulated by the RNA species should be conducted. · Insight into the regulation of the RNA species and how it relates to the pathologic state should be provided. · If applicable: Details of initial screen used to identify RNA species involvement in pathway/disease (number of subjects, statistical tests employed, percent change from controls). |
收录体裁 | |
投稿指南 | https://molmed.biomedcentral.com/submission-guidelines |
投稿模板 | |
参考文献格式 | |
编辑信息 |
|